miR-34a及其下游基因在铁超载大鼠非酒精性脂肪肝发生过程中的作用

doi:10.3969/j.issn.1004-616x.2018.05.010

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (5): 378-383.doi: 10.3969/j.issn.1004-616x.2018.05.010

miR-34a及其下游基因在铁超载大鼠非酒精性脂肪肝发生过程中的作用

曹玥, 孙梦云, 蔡静明, 张立加, 赵艳

哈尔滨医科大学公共卫生学院营养与食品卫生学教研室, 黑龙江哈尔滨 150081

收稿日期:2018-04-09 修回日期:2018-06-08 出版日期:2018-09-30 发布日期:2018-09-30
通讯作者: 赵艳,E-mail:amyzhaosb@163.com E-mail:amyzhaosb@163.com
作者简介:曹玥,E-mail:1530825685@qq.com。
基金资助:
国家自然科学基金（81573136，81273062）

Involvement of miR-34a and its downstream genes plus iron overload in rats with nonalcoholic fatty liver disease

CAO Yue, SUN Mengyun, CAI Jingming, ZHANG Lijia, ZHAO Yan

Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin 150081, Heilongjiang, China

Received:2018-04-09 Revised:2018-06-08 Online:2018-09-30 Published:2018-09-30

摘要/Abstract

摘要： 目的：探讨miR-34a及其下游基因在铁超载大鼠非酒精性脂肪肝（NAFLD）发生过程中的作用。方法：将36只5周龄雄性SD大鼠随机分为对照组（基础饲料）、高铁组（含1% FeSO₄的基础饲料）、高脂组（脂肪供能比为35%的高脂饲料）和高脂高铁组（含1% FeSO₄的高脂饲料）。干预12周后，称取大鼠体质量；肝脏油红O染色观察大鼠肝脏中脂质堆积程度；测定大鼠血清中丙氨酸氨基转移酶（ALT）和天门冬氨酸氨基转移酶（AST）含量；实时荧光定量PCR（qPCR）检测大鼠肝脏中miR-34a、沉默信息调节因子1（SIRT1）及过氧化物酶体增殖物激活受体α（PPARα）的mRNA表达水平，并用Western blot方法检测SIRT1和PPARα的蛋白表达水平。结果：与对照组相比，高脂组和高脂高铁组大鼠体质量、血清ALT及miR-34a表达水平均显著增加（P均 < 0.05），SIRT1及其下游PPARα的mRNA和蛋白表达水平均降低（P均 < 0.05），肝脏脂质堆积程度加重；与高脂组比较，高脂高铁组SIRT1和PPARα的mRNA和蛋白表达水平均显著降低（P均 < 0.05）。结论：高脂高铁联合作用，可进一步激活miR-34a的表达，进而抑制其下游基因的表达，从而加重NAFLD大鼠肝脏脂代谢紊乱。

关键词: 非酒精性脂肪肝, 铁超载, miR-34a, 脂代谢

Abstract: OBJECTIVE:To explore the roles of miR-34a and its downstream genes plus iron overload in rats with nonalcoholic fatty liver disease. METHODS:Thirty-six male SD rats of 5 weeks old were randomly divided into control diet group (basal diet),high iron diet group (basal diet containing 1% FeSO₄),high fat diet group (high fat diet 35% energy supply from fat) and high fat plus high iron diet group (high fat diet containing 1% FeSO₄). These rats were sacrificed after 12 weeks. Body weights were measured and liver lipid accumulation was observed by oil red O staining. The contents of ALT and AST in rat serum were detected. Quantitative real-time PCR (qPCR) was used to detect mRNA levels of miR-34a, silent information regulator (SIRT1) and peroxisome proliferator-activated receptor α (PPARα). SIRT1 and PPARα protein levels were detected by Western blot. RESULTS:Compared with control diet group,the body weight,the serum ALT level and the level of miR-34a in high fat diet group and high fat plus high iron diet group were increased significantly (P < 0.05). The levels of mRNA and protein expression of SIRT1 and its downstream PPARα were decreased (P < 0.05). The degree of lipid accumulation in the liver was gradually aggravated. Compared with high fat diet group,the levels of mRNA and protein expression of SIRT1 and PPARα in high fat plus high iron diet group were decreased significantly (P < 0.05). CONCLUSION:The combined effect of high fat and high iron diets could activate the expression of miR-34a and then inhibit the expression of downstream genes, thus aggravating liver lipid disorder in NAFLD rats.

Key words: nonalcoholic fatty liver disease, iron overload, miR-34a, lipid metabolism

中图分类号:

R587.4

曹玥, 孙梦云, 蔡静明, 张立加, 赵艳. miR-34a及其下游基因在铁超载大鼠非酒精性脂肪肝发生过程中的作用[J]. 癌变·畸变·突变, 2018, 30(5): 378-383.

CAO Yue, SUN Mengyun, CAI Jingming, ZHANG Lijia, ZHAO Yan. Involvement of miR-34a and its downstream genes plus iron overload in rats with nonalcoholic fatty liver disease[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 378-383.

参考文献

[1] SORONEN J,YKI-JÄRVINEN H,ZHOU Y,et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease[J]. Physiol Rep,2016,4(1):e12661.
[2] OTSUKA M, KISHIKAWA T, YOSHIKAWA T, et al. MicroRNAs and liver disease[J]. J Hum Genet,2017,62(1):75-80.
[3] PEREIRA-DA-SLIVA T, COUTINHO CRUZ M, CARRUSCA C, et al. Circulating microRNA profiles in different arterial territories of stable atherosclerotic disease:a systematic review[J]. Am J Cardiovasc Dis,2018,8(1):1-3.
[4] KERR T A, KORENBLAT K M, DAVIDSON N O. MicroRNAs and liver disease[J]. Transl Res,2011,157(4):241-252.
[5] BAFFY G. MicroRNAs in nonalcoholic fatty liver disease[J]. J Clin Med,2015,4(12):1977-1988.
[6] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
[7] GAQQINI M, MORELLI M, BUZZIQOLI E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance,dyslipidemia,atherosclerosis and coronary heart disease[J]. Nutrients,2013,5(5):1544-1560.
[8] ALAM S,MUSTAFA G,ALAM M,et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease[J] World J Gastrointest Pathophysiol,2016,7(2):211-217.
[9] GORI M, ARCIELLO M, BALSANO C. MicroRNAs in nonalcoholic fatty liver disease:novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma[J]. Biomed Res Int,2014,2014:741465.
[10] YAMAKUCHI M,FERLITO M,LOWENSTEIN C J. MiR-34a repression of SIRT1 regulates apoptosis[J]. Proc Natl Acad Sci USA,2008,105(36):13421-13426.
[11] NASSIR F,IBDAH J A. Sirtuins and nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2016, 22(46):10084-10092.
[12] AMACHER D E. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease[J]. Biomarkers, 2014,19(7):541-552.
[13] HUR W, LEE J H, KIN S W, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway[J]. Int J Biochem Cell Biol,2015,64:265-276.
[14] KIM H. The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation[J]. Sci Rep,2016,6:37280.
[15] GUO Y, XIONG Y, SHENG Q, et al. A micro-RNA expression signature for human NAFLD progression[J]. J Gastroenterol,2016,51(10):1022-1030.
[16] SHAN W, GAO L, ZENG W, et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease[J]. Cell Death Dis,2015,6:e1833.
[17] LEE J,PADHYE A,SHARMA A,et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition[J]. J Biolchem,2010,285(17):12604-12611.
[18] TIAN X F,JI F J,ZANG H L,et al. Activation of the miR 34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs[J]. PLoS One,2016,11(7):e0158657.
[19] LI X, LIAN F, LIU C, et al. Isocaloric pair-fed high-carbohydrate diet induced more hepatic steatosis and inflammation than high-fat diet mediated by miR-34a/SIRT1 axis in mice[J]. Sci Rep,2015,5:16774.
[20] PAWLAK M, LEFEBVRE P, STAELS B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease[J]. J Hepatol,2015,62(3):720-733.
[21] QIN S, YIN J, HUANG K. Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPARα and SREBP-1c in L-02 cells[J]. Lipids, 2016,51(7):797-805.
[22] ZHANG Y,CUI Y,WANG X L,et al. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats[J]. Cytokine,2015,75(1):127-135.

miR-34a及其下游基因在铁超载大鼠非酒精性脂肪肝发生过程中的作用

Involvement of miR-34a and its downstream genes plus iron overload in rats with nonalcoholic fatty liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	龙子, 樊隽澍, 吴光源, 王欣, 海春旭. 低剂量双酚A通过调控PPARγ致小鼠糖脂代谢紊乱的研究[J]. 癌变·畸变·突变, 2020, 32(4): 245-255.
[2]	廖鼐, 龙子, 海春旭, 王欣. 2,3,7,8-四氯二苯并二噁英染毒或联合高脂饮食致小鼠糖脂代谢紊乱的实验研究[J]. 癌变·畸变·突变, 2019, 31(2): 111-118.
[3]	沈洁, 蔡静明, 孙梦云, 曹玥, 赵艳. 铁超载对非酒精性脂肪肝病HepG2细胞模型中Hepcidin和Fpn-1的影响[J]. 癌变·畸变·突变, 2017, 29(3): 184-188.
[4]	蔡静明, 沈洁, 曹玥, 孙梦云, 赵艳. 铁超载对高脂饮食诱导的非酒精性脂肪肝病大鼠脂代谢的影响[J]. 癌变·畸变·突变, 2017, 29(3): 179-183.
[5]	方芳, 王静, 马彩玲. miR-34a在新疆维吾尔族和汉族妇女不同宫颈病变组织中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(1): 41-45.